Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
IMS 2022
INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸
Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉
#MPNsm #HemOnc
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...
ow.ly
🎙️ New podcast: Top #ASH25 updates in AML!
➡️Redefining frontline therapy, venetoclax-based triplets, menin inhibition, emerging IOs & more with leading AML experts.
🎧 https://ow.ly/yORY50Y6brB
#AMLsm #Leusm #Leukemia #TrialUpdate #CTSM #ASH25 #HemOnc
In an interview from #ASH25, @akshatdoctor (@LLUMedSchool) discusses real-world experience with the anti-tissue factor pathway inhibitor marstacimab in severe & non-severe #hemophilia, highlighting its potential to revolutionize treatment for patients.
Click to watch: 🎥
🗞️ In a recent paper in @Haematologica, the longest survival to date in any unselected group of patients with #MultipleMyeloma was reported (an average of almost 13 years).
🎥 We caught up with Dr James Berenson (@myelomadoc) to gain insight into the paper & to hear about the
Have you registered for #CART26 yet?🩸
Hear from @ARampotas, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:
🎥
Click here to register your attendance (in
The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy
In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the...
ow.ly
IMS 2022
INCA033989, a novel mutant CALR-specific monoclonal antibody, was a hot topic in the field of MPNs at #ASH25, with promising early results in both #EssentialThrombocythemia & #Myelofibrosis.🩸
Hear more from @harrisoncn1 of @GSTTnhs:
🎥 👉
#MPNsm #HemOnc
Safety & efficacy of INCA033989, a first-in-class mutant CALR-specific mAb, in patients with ET & MF
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK, discusses the safety and ...
ow.ly
🎙️ New podcast: Top #ASH25 updates in AML!
➡️Redefining frontline therapy, venetoclax-based triplets, menin inhibition, emerging IOs & more with leading AML experts.
🎧 https://ow.ly/yORY50Y6brB
#AMLsm #Leusm #Leukemia #TrialUpdate #CTSM #ASH25 #HemOnc
In an interview from #ASH25, @akshatdoctor (@LLUMedSchool) discusses real-world experience with the anti-tissue factor pathway inhibitor marstacimab in severe & non-severe #hemophilia, highlighting its potential to revolutionize treatment for patients.
Click to watch: 🎥
🗞️ In a recent paper in @Haematologica, the longest survival to date in any unselected group of patients with #MultipleMyeloma was reported (an average of almost 13 years).
🎥 We caught up with Dr James Berenson (@myelomadoc) to gain insight into the paper & to hear about the
Have you registered for #CART26 yet?🩸
Hear from @ARampotas, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy:
🎥
Click here to register your attendance (in
The upcoming EBMT-EHA European CAR T-cell meeting 2026: sharing updates in CAR-T & cellular therapy
In this video, Alex Rampotas, MBBS, MRCP, University College London, London, UK, invites viewers to register for the...
ow.ly
